Sean Ellis - 05 Mar 2026 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Reporting relationship: Director
Issuer ticker: ENTX
Reported as of: 05 Mar 2026
Net transaction value: +$12,300
SEC form: 4
Accepted by SEC: 09 Mar 2026, 08:30:21 UTC
Prior SEC filing: 11 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact

Key filing fact

Sean Ellis filed Form 4 for Entera Bio Ltd. (ENTX) on 09 Mar 2026.

Key facts

This page summarizes Sean Ellis's Form 4 filing for Entera Bio Ltd. (ENTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Mar 2026, 08:30.

Change

Previous filing in this sequence was filed on 11 Feb 2026.
Current net transaction value: +$12,300.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001904752 Primary reporting owner

Ellis Sean

Relationship: Director
Address: KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM, ISRAEL
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Signature date: 09 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENTX transaction

Ordinary Shares, par value NIS 0.0000769 per share

Purchase

Transaction value: $12,300
Shares: +10,000
Change %: +5.6%
Price: $1.23
Shares after: 188,098
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2287 to $1.245 inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.